|Articles|June 13, 2023
Transduction for AAV with Sean Hart
Author(s)Chris Spivey
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.
Advertisement
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured. The full discussion can and more can be viewed
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Launch in Lockstep: Biopharma Readiness for the CNPV’s Accelerated Clock
2
How Miniaturized Analytics Are Transforming Aseptic Bioprocessing Control
3
CDC’s Policy Shift on Autism and Vaccines Spurs Biopharma Quality/System Concerns
4
Industry Experts Probe CNPV Impacts
5
